What is the current stock price of Bicara Therapeutics Inc. Common Stock (BCAX)?

As of the latest market data, Bicara Therapeutics Inc. Common Stock (BCAX) is trading at $21.68. The stock has seen a gain of 4.03% today.

Does Bicara Therapeutics Inc. Common Stock (BCAX) pay a dividend?

Based on current data, Bicara Therapeutics Inc. Common Stock does not have a confirmed active dividend policy.

What is the market cap of Bicara Therapeutics Inc. Common Stock?

The current market capitalization of Bicara Therapeutics Inc. Common Stock (BCAX) is approximately unavailable.

BCAX

Bicara Therapeutics Inc. Common Stock·Healthcare

21.68

4.031%(+0.84)

Market Closed

26.25

21.079%(+4.57)

After Hours

Last Updated: — ET

52W L: $8.4852W H: $24.25

BCAX NEWS

seekingalpha.com

1d ago

Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript

marketbeat.com

1d ago

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics NASDAQ: BCAX said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the company as Ficara, in first-line recurrent or metastatic HPV-negative head and neck cancer.

globenewswire.com

1d ago

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

fool.com

May 15

Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet

This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.

marketbeat.com

May 14

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics NASDAQ: BCAX said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference.

seekingalpha.com

May 13

Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Company Profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2024-09-13

Beta

-0.56

Websitewww.bicara.com↗